Personalized ctDNA micro-panels can monitor and predict clinical outcomes for patients with triple-negative breast cancer
Erica K. Barnell(Washington University in St. Louis), Foluso O. Ademuyiwa(Washington University in St. Louis), Anamika Basu(James S. McDonnell Foundation), Meenakshi Anurag(Baylor College of Medicine), Malachi Griffith(Washington University in St. Louis), Bryan Fisk(Washington University in St. Louis), Jingqin Luo(Washington University in St. Louis), Zachary L. Skidmore(James S. McDonnell Foundation), Catrina C. Fronick(Washington University in St. Louis), Matthew J. Ellis(Washington University in St. Louis), Robert S. Fulton(St. Jude Children's Research Hospital), Aparna Anand(James S. McDonnell Foundation), Obi L. Griffith(Washington University in St. Louis), Megan M. Richters(James S. McDonnell Foundation), Kelsy C. Cotto(James S. McDonnell Foundation)
Cited by 14
Related Papers
The clonal and mutational evolution spectrum of primary triple-negative breast cancers
|Nature|2012|2k
Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia
|New England Journal of Medicine|2014|1.4k
A draft human pangenome reference
|Nature|2023|1.1k